06/19/2017 | Press release | Distributed by Public on 06/19/2017 17:26
On June 19, 2017, the online media outlet Business Insider published a reporter's 'editorial' regarding Mallinckrodt, its drug H.P. Acthar Gel and its relationship with Express Scripts specific to that product. In light of the misleading allegations in this opinion piece, the company believes it is important to reinforce the facts about this arms-length business relationship.
Mallinckrodt engages with a variety of partners in all parts of the industry value chain to ensure access for appropriate patients who are prescribed H.P. Acthar Gel. The company contracts with the majority of the largest Pharmacy Benefit Managers in the U.S, among them Express Scripts.
As is common practice for self-administered, injectable products that are not stocked at neighborhood pharmacies and require special climate-controlled handling, Mallinckrodt utilizes a network of independent specialty pharmacies to deliver Acthar to patients who have been prescribed the medicine. Mallinckrodt has individual contracts with each of the independent specialty pharmacies in its network, of which Accredo, a specialty pharmacy owned and operated under the Express Scripts umbrella, is one. The pharmacies Mallinckrodt contracts with are selected based on a number of criteria, including their overall ability to fulfill prescriptions and provide product to patients in a timely manner.
To deliver Acthar to its network of independent specialty pharmacies who then deliver the medicine to patient's homes, Mallinckrodt also contracts with Express Scripts' subsidiary CuraScript SD.
Mallinckrodt also has two other contracts with another separately owned Express Scripts subsidiary, United BioSource Corporation - one to manage order processing for the product, and another to conduct income or means testing for a program under which Mallinckrodt provides free product to low-income, uninsured or underinsured patients who qualify.
Utilization of all these services is a standard industry practice for most specialty pharmaceutical drugs, of which H.P. Acthar Gel is one.
For further information regarding H.P. Acthar Gel, please see: http://www.mallinckrodt.com/about/news-and-media/2263463
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations
Senior Communications Manager
Chief Public Affairs Officer